Drugs / Cam2020 M2SR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05163847 | Jun → Nov 2022 | — | FluGen Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-08-02 | FluGen Inc | Results FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus flugen.com ↗
Results published in the Journal of Infectious Diseases show that subjects with vaccine-induced neutralizing antibodies were protected against infection and illness following challenge with an antigenically distinct virus. |
| 2017-08-16 | FluGen Inc | Results M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza flugen.com ↗
All M2SR vaccinated mice survived lethal challenge with influenza A/Vietnam/1203/2004 (H5N1), whereas 40% of mice vaccinated with recombinant H5 HA and none of the naïve controls survived. |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cam2020 M2SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163847 ↗ |
| Known as | M2SR | “the intranasal H3N2 M2-deficient single-replication (M2SR) vaccine” PMID 39004096 ↗ Jul 2024 |
| Modality | Vaccine | “the intranasal H3N2 M2-deficient single-replication (M2SR) vaccine” PMID 39004096 ↗ Jul 2024 |
| Route | Intranasal | “Administered intranasally on Day 1” NCT05163847 ↗ |